1. Neurodevelopmental follow-up at five years corrected age of extremely low birth weight infants after postnatal replacement of 17β-estradiol and progesterone.
- Author
-
Trotter A, Steinmacher J, Kron M, and Pohlandt F
- Subjects
- Child Development drug effects, Child, Preschool, Double-Blind Method, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Treatment Outcome, Child Development physiology, Estradiol therapeutic use, Hormone Replacement Therapy methods, Infant, Extremely Low Birth Weight growth & development, Progesterone therapeutic use
- Abstract
Context: Extremely low birth weight (ELBW) infants are prone to impaired neurodevelopment., Objective: The aim was to determine long-term neurodevelopmental outcome in ELBW infants after postnatal 17β-estradiol (E2) and progesterone (P) replacement., Design: At 5-yr corrected age, ELBW infants were assessed for standardized cognitive and neurological outcome after postnatal randomized E2 and P replacement or placebo administration., Setting: The follow-up examination was performed in a neuropediatric ambulatory care center., Patients: Sixty-one of 71 surviving infants (86%) were available for follow-up., Main Outcome Measures: Cognitive and neurological outcome was evaluated using the Kaufmann Assessment Battery for Children, the Gross Motor Function Classification Scale, and clinical neurological examination., Results: No significant differences were found between the replacement and placebo groups for the Gross Motor Function Classification Scale, presence of paresis, cerebral palsy, spasticity, and ametropia. However, a significant time-response relationship was found with E2 and P replacement. Every day of treatment reduced the risk for cerebral palsy (P=0.03), spasticity (P=0.01), and ametropia (P=0.01)., Conclusion: Postnatal E2 and P replacement may have potential in improving neurodevelopmental outcome in ELBW infants. Larger trials are needed to test this new hypothesis.
- Published
- 2012
- Full Text
- View/download PDF